Challenges in Cellular Immunotherapy in Cancer Treatment

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 399

Special Issue Editor


E-Mail Website
Guest Editor
1. Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany
2. Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany
Interests: lung cancer; biomarkers; tumor immunology; targeted therapy; immunotherapy; Resistance mechanism; mouse models

Special Issue Information

Dear Colleagues, 

Cell-based cancer therapies are continuously evolving and improving, not only in the treatment of hematologic malignancies but also in solid tumors. Prominent cellular cancer therapies comprise T cell-based and natural killer (NK) cell-based therapies engineered with synthetic chimeric antigen receptors (CARs).

A successful anti-tumor effect of cellular immunotherapies harbors several challenges. Engineered and/or expanded cells need to be produced in sufficient amounts, they have to target the tumor cell appropriately and infiltrate the tumor.

In hematologic malignancies, cellular immunotherapies have three main limitations: (1) toxicities, (2) graft-versus-host disease (GvHD), and (3) disease progression in an antigen-positive or an antigen-negative manner. Moreover, tumor cells can perform a lineage switch after the application of engineered cells.

Especially in solid tumors, a selection of less immunogenic tumor cells is a well-described phenomenon. Other mechanisms contributing to the tumor relapse are an immunosuppressive micromilieu and neovascularization hindering immune cell infiltration and effector function and leading to hypoxia. Last but not least, in solid cancers the identification of a proper tumor-associated antigen is demanding.

Based on your expertise in cellular immunotherapy, you are invited to contribute a research paper or review in this Special Issue to highlight the remaining challenges for clinicians: to achieve a maximal, selective and persisting anti-tumor immune response in patients suffering from rapidly progressive cancers. Studies focusing on B cell-based and DC-based immunotherapy, and pre-clinical investigations are also welcome.

Dr. Lydia Meder
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adoptive cellular therapy
  • T cells
  • CARs
  • NK cells
  • solid cancers
  • tumor antigens
  • dendritic cells
  • B cells
  • toxicities
  • GvHD

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop